Cagrilintide and Weight Loss: What Trials Show vs. Real Life

Cagrilintide at a glance:

• Drug class: Long-acting amylin analog
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Receptor target: amylin receptors (calcitonin receptor + RAMP)

Weight loss with Cagrilintide is durable as long as the medication is continued. Stopping leads to weight regain in most users — that's a feature of how the biology works, not a failure of the drug.

How Much Weight Loss to Expect

Monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%. The headline number from trials is the average — your result will fall somewhere on the distribution around that average.

For planning purposes:

• Strong responders: top quartile of trial average
• Average responders: at or near the trial average
• Lower responders: bottom quartile (still typically meaningful, but less than the headline)

The Time Course

For Cagrilintide on a weight-loss trajectory, expect the following pattern:

• Months 1-2 (titration): modest scale change; mostly habit shifts
• Months 2-6: the bulk of weight loss happens here for incretin therapies
• Months 6-12: continued slower progress; first plateaus appear
• Year 2+: maintenance becomes the central question

See our Cagrilintide timeline page for week-by-week detail.

Adjusting Lifestyle on Cagrilintide

The medication makes appetite changes easier; it doesn't substitute for them. Users who succeed long-term tend to:

• Eat smaller, more frequent meals (delayed gastric emptying makes large meals uncomfortable)
• Prioritize protein (helps preserve lean mass during weight loss)
• Stay hydrated (reduces nausea and supports kidney function)
• Maintain or increase resistance training (preserves lean mass)

Plateau Management

Most users hit a plateau around month 9-12. Options at that point:

• Confirm dose is at maintenance and no titration steps were skipped
• Reassess diet quality and timing
• Increase resistance training
• Discuss escalation or switching with a clinician

For specific plateau strategies, see our plateau guide.

Stopping and Maintenance

The hardest part of GLP-1 weight loss isn't reaching the goal — it's keeping the weight off. Trial extension data show 60-70% of lost weight returns within a year of stopping. Long-term maintenance usually requires sustained medication use.

If you and your clinician decide to taper, do it gradually and pair with intensified lifestyle support.

Cost Reality Check

Weight loss with Cagrilintide is a long game. At current pricing, annual cost is meaningful — see our Cagrilintide cost guide for budget planning.

Bottom Line

The weight-loss conversation around Cagrilintide usually focuses on the loss phase. The harder conversation — and the one that determines long-term outcome — is about maintenance.

Frequently Asked Questions

Related Reading

• The Honest Guide to Cagrilintide: What Patients and Doctors Actually Say
• Cagrilintide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Cagrilintide Results: Realistic Expectations vs. Trial Headlines
• Why Cagrilintide Costs So Much (and 5 Ways to Pay Less)
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

Individual results vary. This page is informational and is not personalized medical advice.